RETN

RETN Full Name

resistin

RETN Introduction

RETN (Resistin) has emerged as a clinically important target at the intersection of obesity, chronic inflammation, insulin resistance, and cardiovascular disease. Encoded by the RETN gene on chromosome 19p13.2, resistin belongs to a cysteine-rich adipokine family and is increasingly recognized for its ability to connect metabolic stress with immune dysfunction. Many patients struggling with obesity, type 2 diabetes, or unexplained inflammatory complications often experience persistent metabolic imbalance even after lifestyle intervention, highlighting the need for biomarkers that reflect both inflammatory and metabolic burden. Research over the past decade has shown that elevated circulating resistin levels are associated with poor metabolic health, endothelial dysfunction, and increased cardiovascular risk. Human genetic studies have further linked RETN promoter polymorphisms, especially rs1862513, with higher serum resistin expression, obesity susceptibility, coronary artery disease severity, and impaired glucose metabolism, making RETN a valuable candidate for precision medicine and translational biomarker development.

Functionally, resistin acts as a potent regulator of inflammatory signaling rather than simply a metabolic hormone. In humans, the protein is primarily secreted by macrophages and peripheral immune cells, where it amplifies cytokine production, promotes endothelial activation, and drives chronic low-grade inflammation. This inflammatory activity is particularly relevant in metabolic disorders where adipose tissue dysfunction and immune activation coexist. Recent mechanistic studies identified the Resistin/TLR4/miR-155-5p signaling axis as a key pathway involved in hypothalamic neuroinflammation induced by high-fat diets. Through Toll-like receptor 4 activation, resistin enhances microglial activation and inflammatory microRNA expression, contributing to impaired glucose tolerance and obesity-associated central nervous system inflammation. These findings provide important insight into why many obese patients develop persistent metabolic dysregulation even before overt diabetes appears. In parallel, studies have shown that resistin interacts with Cyclase-Associated Protein 1 (CAP1) and may function downstream of cannabinoid receptor signaling pathways, linking RETN to insulin resistance, macrophage activation, and vascular inflammation.

The disease relevance of Resistin signaling continues to expand across cardiometabolic, inflammatory, and neurodegenerative research fields. Elevated resistin levels have been repeatedly associated with atherosclerosis, coronary artery disease, heart failure progression, rheumatoid arthritis, sepsis, and metabolic syndrome. In cardiovascular disease, resistin contributes to endothelial dysfunction, smooth muscle proliferation, oxidative stress, and plaque instability, all of which accelerate vascular injury and adverse cardiac remodeling. In obesity-related disorders, resistin serves as both a pathogenic mediator and a measurable biomarker reflecting inflammatory severity. Its stable multimeric structure and detectable serum expression also make it attractive for diagnostic assay development and therapeutic monitoring. As pharmaceutical research increasingly focuses on inflammation-driven metabolic disease, RETN and its downstream signaling partners are gaining attention as promising targets for anti-inflammatory therapies, insulin-sensitizing strategies, and precision interventions aimed at reducing obesity-associated cardiovascular complications.

Alternate Names for RETN

RETN; resistin; ADSF; Rstn; Xcp4; Fizz3; found in inflammatory zone 3; cysteine-rich secreted protein FIZZ3; adipose tissue-specific secretory factor; dominant inhibitory adipocyte-specific secretory factor; adipose-specific cysteine-rich secreted protein A12-alpha;

• 1.Ling Y, et al.; Resistin in cardiac diseases: from molecular mechanisms to clinical implications. Front Endocrinol (Lausanne). 2025, 16:1708332.
  2.Tripathi D, et al.; Resistin in metabolism, inflammation, and disease. FEBS J. 2020, 287(15):3141-3149.